RU2019112165A3 - - Google Patents

Download PDF

Info

Publication number
RU2019112165A3
RU2019112165A3 RU2019112165A RU2019112165A RU2019112165A3 RU 2019112165 A3 RU2019112165 A3 RU 2019112165A3 RU 2019112165 A RU2019112165 A RU 2019112165A RU 2019112165 A RU2019112165 A RU 2019112165A RU 2019112165 A3 RU2019112165 A3 RU 2019112165A3
Authority
RU
Russia
Application number
RU2019112165A
Other languages
Russian (ru)
Other versions
RU2019112165A (ru
RU2798988C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2019112165A publication Critical patent/RU2019112165A/ru
Publication of RU2019112165A3 publication Critical patent/RU2019112165A3/ru
Application granted granted Critical
Publication of RU2798988C2 publication Critical patent/RU2798988C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35Valency
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RU2019112165A 2016-09-23 2017-09-20 Биспецифические трехвалентные антитела, связывающиеся с клаудином 6 или клаудином 18.2, и cd3, для лечения онкологических заболеваний с экспрессией клаудина RU2798988C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2016/072688 2016-09-23
PCT/EP2016/072688 WO2018054484A1 (en) 2016-09-23 2016-09-23 Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
PCT/EP2017/073773 WO2018054973A1 (en) 2016-09-23 2017-09-20 Bispecific trivalent antibodies binding to claudin6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2023113612A Division RU2023113612A (ru) 2016-09-23 2017-09-20 Биспецифические трехвалентные антитела, связывающиеся с клаудином 6 или клаудином 18.2 и cd3, для лечения онкологических заболеваний с экспрессией клаудина

Publications (3)

Publication Number Publication Date
RU2019112165A RU2019112165A (ru) 2020-10-23
RU2019112165A3 true RU2019112165A3 (enExample) 2021-01-20
RU2798988C2 RU2798988C2 (ru) 2023-06-30

Family

ID=

Also Published As

Publication number Publication date
CA3034186A1 (en) 2018-03-29
SG11201901899PA (en) 2019-04-29
JP7055794B2 (ja) 2022-04-18
AU2017331331A1 (en) 2019-02-07
AU2017331331B2 (en) 2022-03-10
MX2023005375A (es) 2023-05-22
JP2019535234A (ja) 2019-12-12
US20240158501A1 (en) 2024-05-16
AU2022200283A2 (en) 2022-04-21
ZA202002471B (en) 2021-09-29
JP2024054250A (ja) 2024-04-16
ZA201900962B (en) 2020-10-28
IL290234A (en) 2022-03-01
WO2018054973A1 (en) 2018-03-29
CN118388656A (zh) 2024-07-26
US11787862B2 (en) 2023-10-17
RU2019112165A (ru) 2020-10-23
JP7436552B2 (ja) 2024-02-21
KR102537091B1 (ko) 2023-05-31
NZ750132A (en) 2023-05-26
IL290230A (en) 2022-03-01
IL264233B (en) 2022-03-01
KR20190052002A (ko) 2019-05-15
US20190309067A1 (en) 2019-10-10
KR20230074637A (ko) 2023-05-30
CN110023336B (zh) 2024-05-17
EP3515939A1 (en) 2019-07-31
WO2018054484A1 (en) 2018-03-29
AU2022200283A1 (en) 2022-02-17
MX2019003350A (es) 2019-08-12
EP4043494A1 (en) 2022-08-17
IL264233A (en) 2019-02-28
BR112019002168A2 (pt) 2019-09-17
CN110023336A (zh) 2019-07-16
AU2025202697A1 (en) 2025-05-08
JP2022091973A (ja) 2022-06-21

Similar Documents

Publication Publication Date Title
BR112018003417A2 (enExample)
BR112019008128A2 (enExample)
BR112019000402A2 (enExample)
BR112019009203A2 (enExample)
BR112019003108A2 (enExample)
BR202016016457U2 (enExample)
CN303633657S (enExample)
CN303537770S (enExample)
CN303538779S (enExample)
CN303538765S (enExample)
CN303667161S (enExample)
CN303659134S (enExample)
CN303538546S (enExample)
CN303656648S (enExample)
CN303538537S (enExample)
CN303538530S (enExample)
CN303538479S (enExample)
CN303538101S (enExample)
CN303646015S (enExample)
CN303645825S (enExample)
CN303538091S (enExample)
CN303538067S (enExample)
CN303641354S (enExample)
CN303538001S (enExample)
CN303578921S (enExample)